Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (2010 - 2026)

Vanda Pharmaceuticals has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$48.5 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$48.5 million, down 64.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 441.53% YoY), and the FY2025 annual result was -$220.5 million, down 1066.53% from the prior year.
• Net Income towards Common Stockholders came in at -$48.5 million for Q1 2026 at Vanda Pharmaceuticals, up from -$141.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $6.9 million in Q4 2022 to a low of -$141.2 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$4.5 million (2024), against an average of -$16.4 million.
• Across the five-year window, Net Income towards Common Stockholders soared 150.2% in 2023 and plunged 4000.73% in 2024, its largest moves.
• Vanda Pharmaceuticals' Net Income towards Common Stockholders stood at $6.9 million in 2022, then plunged by 134.85% to -$2.4 million in 2023, then sank by 103.93% to -$4.9 million in 2024, then plunged by 2796.41% to -$141.2 million in 2025, then jumped by 65.64% to -$48.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$48.5 million (Q1 2026), -$141.2 million (Q4 2025), and -$22.6 million (Q3 2025), per Business Quant data.